Ivivc sahilhusen


Published on

Published in: Health & Medicine
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Ivivc sahilhusen

  3. 3. 3 WHAT IS IVIVC??? • In IVIVC, "C" denotes "Correlation", which means "the degree of relationship between two variables". This term does not limit a relationship to only the linear type, but allows for non-linear relationships as well. USP definition • “The establishment of rational relationship b/w a biological property or a parameter derived from a biological property produced by a dosage form and physicochemical property of same dosage form” • Conceptually, IVIVC describes a relationship between the in vitro dissolution / release versus the in vivo absorption. FDA definition • “A predictive mathematical model describing relationship between in-vitro property of a dosage form and in-vivo response.”
  4. 4. 4 IVIVC BASIC • Simply a mathematical model describing the relationship b/w in vitro and in vivo properties of drug. • In vitro –in vivo correlation can be achieved using Pharmacological correlation “Based on clinical observations” Semi quantitative correlation “Based on the drug blood levels or urinary excretion data” Quantitative correlation “Arising from absorption kinetics and calculation of in vivo dissolution rate and absorption rate constants”
  5. 5. 5 CRITERIA FOR IVIVC • Successful IVIVC can be developed when in-vitro dissolution is rate limiting step in absorption and appearance of drug in in- vivo circulation following oral or other routes of administration. • These studies are to be conducted during the early stages of drug product development in order to select the most effective formulation and to establish appropriate dosage regimen. • The release- controlling excipients in the formulations should either be identical or very similar.
  6. 6. 6 OBJECTIVE OF IVIVC • To reduce the number of human studies during the formulation development • To serve as a surrogate for in vivo bioavailability • To support biowaivers. • To validates the use of dissolution methods and specification settings(This is because the IVIVC includes in vivo relevance to in vitro dissolution specifications). • To assist quality control for certain scale-up and post-approval changes (SUPAC). • Due to all above objective, such IVIVC leads to 1. Shortens the drug development period, 2. Economizes the resources and 3. Leads to improved product quality.
  7. 7. 7 NEED FOR IVIVC • Theoretically, correlation of in-vivo absorption rate with clinical response will be the most worthwhile approach. But, clinical approach is a poor tool for accurate measurement of bioavailability. • Determination of drug level at the site of administration would be next logical approach. But again, with some exceptions, it‘s impossible. • Urinary excretion analysis of drug is meaningful for establishing IVIVC but due to complicated pharmacokinetic considerations, such as drug metabolism and urine collection problems.thus it is generally assumed that blood(serum/plasma) level measurements give a better assessment of bioavailability and bioequivalence. • This relationship is an important item of research in the development of drug delivery systems. • A good IVIVC model can explore the relationship between in vitro dissolution or release and in vivo absorption profiles. • The IVIVC model relationship facilities the rational development and evaluation of immediate or extended release dosage form as a tool for formulation screening ,in setting dissolution specifications and as a surrogate for bioequivalence testing.
  8. 8. 8 To reduce the number of human studies To explore the relationship To assist quality control for certain SUPAC. Research tool for Formulation Screening IMPORTANCE OF IVIVC To support biowaivers for bioequivalence testing As a surrogate of in vivo bioavailability To set the dissolution specifications Development of drug delivery systems.
  9. 9. 9 FACTORS AFFECTING DEVELOPMENT OF A PREDICTABLE IVIVC 1. Complexity of the delivery system. 2. Composition of formulation. 3. Method of manufacture. 4. Physicochemical properties. 5. Dissolution method.
  10. 10. 10 1. Physicochemical properties of drug A. Factors affecting solubility a. Polymorphism b. Amorphous state and solvation c. Free acid, free base or salt form d. Complexation, solid solutions and eutectics e. Particle size f. Surfactant B. Factors affecting surface area available for dissolution a. Particle size b. Manufacturing variables • The physicochemical properties of the drug substance can assume a primary role in controlling its dissolution from the dosage form. • The aqueous solubility of the drug is one of the major factors that determine its dissolution rate.
  11. 11. 11 • Some studies concluded that the drug solubility data can be used as rough predictor of the possibility of any future problems with bioavailability. • Some of the more prominent physicochemical properties of the drug that influence the dissolution rate are discussed below. Polymorphism • Polymorphic forms of a drug substance are an indicative of different crystalline forms. With a change in the crystalline form, there is a change in the lattice energy level associated with each form. • This energy is responsible for physicochemical properties such as solubilizing potential and dissolution rate. • Metastable (high activation energy) polymorphic forms have better dissolution than stable forms. • This phenomenon is particularly applicable to steroids. • As a result, crystallographic modifications can significantly influences dissolution of drug substance itself as well as the dosage unit it is contained within.
  12. 12. 12 2. Factors related to Composition of formulation • Most solid dosage forms incorporate more than one excipient for various purposes together with the active ingredient in the formulation. The dissolution rate of a pure drug can be altered significantly when mixed with various adjuncts. • These adjuncts include diluents, binders, lubricants, granulating agents, disintegrants, etc. a. b. c. d. e. f. g. Excipients and additives Binders and granulating agents Disintegrating agents Lubricants Surfactants Water soluble dyes Coating polymers
  13. 13. 13 Surfactants • They enhance the dissolution rate of poorly soluble drug. This is due to lowering of interfacial tension between the drug and dissolution medium, increasing effective surface area, which in turn results in faster dissolution rate. • Additionally, the method of incorporation of surfactant in the drug product formulations can markedly affect the dissolution characteristics of the relatively hydrophobic drug. • E.g Non-ionic surfactant Polysorbate 80 increase dissolution rate of phenacetin granules. The increase was more pronounced when the surfactant was sprayed on granules than when it was dissolved in gelatin as granulating agent. Water soluble dyes • Dissolution rate of single crystal of sulphathiazole was found to decrease significantly in presence of FD&C Blue No.1. The inhibiting effect was related to preferential adsorption of dye molecules on primary dissolution sources of crystal surfaces. They inhibit the micellar solubilization effect of bile salts on drug. • Cationic dyes are more reactive in lower conc. than are anionic dyes.
  14. 14. 14 Lubricants • Lubricants that are commonly incorporated in the formulation of solid dosage forms fall predominantly in the class of hydrophobic compounds. • The nature, quality, quantity and method of addition of the lubricant can affect the dissolution rate. It should be added in small amount (1% or less) and should be tumbled or mixed gently for only very short time. Prolonged mixing increases the dissolution time. • Stearates and talc are hydrophobic in nature tend to retard the dissolution rate by decreasing the effective surface drug solvent interfacial area by changing the surface characteristics of the tablets, which reduces wettability and prolonging its disintegration time. • If an enhancing effect in dissolution of hydrophobic granules is desired, water soluble lubricant such as SLS or CARBOWAXES may be used.
  15. 15. 15 3. Method of manufacture a. b. c. d. e. Method of granulation Granule size Compression force Drug- excipient interaction Storage of dosage form Granule size • The nature of the granule affects the dissolution rate of the dosage form. The granule size has little effect on the dissolution rate if the granules are relatively soft and disintegrate easily. However, if they are harder and disintegrate more slowly, the granule size will be of importance and an increase in size will cause a decrease in dissolution rate.
  16. 16. 16 Storage of dosage form • The effect of aging of tablets, capsules and other solid dosage forms should always result in a decrease in a dissolution rate. However, an increase in dissolution rate may also be found. In many cases, however, there is no effect at all. • Dissolution rate of Hydrochlorthiazide tablets granulated with acacia exhibited decrease in dissolution rate during 1 yr of aging at R.T. A similar decrease was observed in tablets stored for 14 days at 50-80ºC or for 4 weeks at 37ºC. • For tablets granulated with PVP there was no change at elevated temperature but slight decrease at R.T. Tablets with starch gave no change in dissoln rate either at R.T. or at elevated temperature. Drug- excipient interaction • These interactions occur during any unit operation such as mixing, milling, blending, drying, and/or granulating result change in dissolution. • The dissolution of prednisolone found to depend on the length of mixing time with Mgstearate Similar as increase in mixing time of formulation containing 97 to 99% microcrystalline cellulose or another slightly swelling disintegrant result in enhance dissolution rate. • Polysorbate-80 used as excipient in capsules causes formation of formaldehyde by autoxidation which causes film formation by denaturing the inner surface of
  17. 17. 17 Compression force • The compression process influence density, porosity, hardness, disintegration time &dissolution of tablet. • First condition, higher compression force increase the density & hardness of tablet, decrease porosity & hence penetrability of solvent into the tablet retard the wettability by forming a firmer & more effective sealing layer by the lubricant and in many case tighter bonding between the particle so decrease dissolution rate of tablet.
  18. 18. 18 • Second condition, higher compression force cause deformation, crushing or fracture of drug particles into smaller ones or convert spherical granules into disc shaped particles with a large increase in the effective surface area so increase in dissolution rate. • Combination of both conditions can occur; • In short dissolution decrease at lower pressure (better bonding), then increase at higher pressure (crushing effect) and decrease again with further increase in pressure bcz of extra rebonding and formation of denser tablets with poorer dissolution characteristics.
  19. 19. 19 4. Factors related to complexity of delivery system • Among the most significant factors that control the process of dissolution are the type and nature of the dosage form within which the active ingredient is contained. • The process of dissolution of an active ingredient from solid pharmaceutical dosage forms involves several intermediate physicochemical steps, such as wetting, swelling capillarity, solubility and diffusion. • With the exception of non disintegrating dosage forms, most solid dosage forms undergo a somewhat common sequence of events during the process of dissolution in vitro. • These events can be delineated as three different types of descriptive categories: A. Process parameters B. Theoretical parameters C. Dissolution testing device parameters
  20. 20. 20 A. Process parameters Parameters modelistic (theoretical) Dissolution testing Device NO Process 1 Introduction of dosage form In dissolution medium Wetting of dosage form Type of device 2 Sampling Penetration of dissolution medium into the dosage unit Operating characteristics 3 Assay De-aggregation and / or de-agglomeration Wetting of drug Solubilization /dissolution of the drug
  21. 21. 21 B. Theoretical parameters 1. Wetting of dosage unit 2. De-aggregation /De-agglomeration 3. Dissolution of powders 4. Dissolution of capsules 5. Dissolution of tablets 6. Dissolution of suppositories 7. Dissolution of suspensions 8. Dissolution of modified release dosage forms Wetting of dosage unit •The first step in the process of dissolution is the wetting of the external surface of the dosage form. The degree and extent to which the surface is wetted are a function of the interfacial tension at the solid liquid interphase. Additionally, the process of wetting is a function of the contact angle the liquid makes with the solid surface. •The more hydrophobic the powder is, the slower the wetting and subsequent penetration of the dissolution medium across the solid surface barrier. •In the case of the tablets, granules prepared by the wet granulation process can produce lower contact angle values, a result attributed to the hydrophilization phenomenon associated with hydrophobic surfaces, thus promoting wetting.
  22. 22. 22 5.Environmental factors during Dissolution a) Factors related to the dissolution testing apparatus 1. 2. 3. 4. 5. 6. 7. 8. b) Eccentricity of agitating (stirring) element Vibration Agitation intensity Stirring element alignment Flow pattern disturbances Sampling probes, position and filters Dosage form position Type of device Factors related to dissolution test parameters 1. Dissolution medium 2. Temperature - Viscosity - Volume of dissolution medium and sink conditions - Dissolved gases – air - Dissolution composition media and pH
  23. 23. 23 Eccentricity of agitating (stirring) element • Official compendium specifies that the stirring shaft must rotate without significant wobble. Eccentricity can induce and propagate changes in hydrodynamic conditions and flow patterns that can, influence the dissolution behavior of the product. Vibration • It can affect change in the flow patterns of the dissolution medium. Additionally, it can introduce unwanted energy to the dynamic system. Both effects may result in significant changes in dissolution rate. • It must be noted that no device is free of vibration. The objective of conducting dissolution testing should be to reduce vibration from external sources to a manageable level that will not introduce significant variation in results from successive dissolution tests on the same product. Stirring element alignment • USP states that the axis of the stirring element must not deviate more than 2 mm from the axis of the dissolution vessel. • A series of tests suggest that a tilt in excess of 1.5 0 may increase in dissolution rates using method 2 from 2 to 25%.
  24. 24. 24 SOME COMMAN TERMS A) MEAN ABSORPTION TIME: The mean time required for drug to reach systemic circulation from the time of drug administration. MAT = MRToral - MRTi.v. B) MEAN IN-VIVO DISSOLUTION TIME: It reflects the mean time for drug to dissolve in-vivo. For solid dosage form: MDTsolid = MRTsolid - MRTsolution. C) MEAN RESIDENCE TIME: The mean time that the drug resides in the body. Also known as mean transit time. MRT = AUMC / AUC. Where, AUMC = Area under first moment Curve (Concentration*time Vs time) AUC = Area under curve (Concentration Vs time) D) PERCENT PREDICTION ERROR: % PE = [(observed value - Predicted value) / observed value] x 100
  26. 26. 26 1. LEVEL A CORRELATION • • • 1. 2. • • • Point-to-Point relationship Usually Correlations are linear, and no formal guidance on the non-linear IVIVC. The data treatment involves a two stage Deconvolution Method. Estimation of the in vivo absorption profile using Wagner-Nelson or Loo-Riegelman method Comparison of fraction of drug absorbed (Fa) and fraction of drug dissolved (Fd) invitro to obtain a linear correlation. Formulations showing Level A correlation require no additional human studies to justify change in manufacturing site, raw material supplier or minor formulation changes. Most informative and very useful from a regulatory perspective. PURPOSE – DEFINE DIRECT RELATIONSHIP
  27. 27. 27 Importants of level A correlation • Providing process control and quality assurance • Determining stable release characteristics of the product over time. • facilitating certain regulatory determinations (e.g.,absence of effect of minor formulation changes or of change in manufacturing site on performance).
  28. 28. 28 2. LEVEL B CORRELATION • A predictive model for relationship between summary parameters that characterize the in-vitro and in-vivo time course. • No point to point correlation • It compares 1. MDT vitro to MDT vivo, 2. MDT vitro to MRT, 3. In-vitro Dissolution Rate Constant (kd) to Absorption Rate Constant (ka). • Comparison using Statistical moment analytical method. • This type of correlation uses all of the in vitro and in vivo data. • This is of limited interest and least useful for regulatory purposes because more than one kind of plasma curve produces similar MRT.
  29. 29. 29 3. LEVEL C CORRELATION • Mathematical model of relationship between the amount of drug dissolved in-vitro at a particular time and a summary pharmacokinetic parameter that characterizes in-vivo time course. (e.g., Cmax, Tmax, T1/2 or AUC). • Single point correlation • Level C correlations can be useful in the early stages of formulation development when pilot formulations are being selected. • Lowest correlation level • Does not reflect a complete shape of plasma concentration time curve.
  30. 30. 30 4. MULTIPLE LEVEL C CORRELATIONS • It relates one or more pharmacokinetic parameters to the percent drug dissolved at several time points of dissolution profile and thus may be more useful. • If a multiple Level C correlation is possible, then a Level A correlation is also likely and is preferred. Level In vitro In vivo A Dissolution curve Input (absorption) curves B Statistical Moment: MDT Statistical Moment: MRT, MAT C Disintegration time, Time to have 10, 50, 90% Dissolved, Dissolution rate, Dissolution efficiency Cmax, Tmax, Ka, Time to have 10, 50, 90% absorbed, AUC
  31. 31. 31 5. LEVEL D CORRELATION • Level D correlation is a rank order and qualitative analysis and is not considered useful for regulatory purposes. It is not a formal correlation but serves as an aid in the development of a formulation or processing procedure. NOTE:• Level B and C correlations can be useful in early formulation development, including selecting the appropriate excipients, to optimize manufacturing processes, for quality control purposes, and to characterize the release patterns of newly formulated immediate-release and modified-release products relative to the reference.
  32. 32. Overall Approach IVIVC Scale factor 1 API – Physicochemical Properties 2 Dosage Form Properties 3 BCS Class PK Data IVIVR Biorelevent Dissolution Computer Modeling Using Convolution including Transporters, PK Models, and PK Parameters, API properties or Drug Release Data Wang et al (2009) Diss Tech, 8, 6-12
  34. 34. 34 1. SIMPLE POINT TYPE • The percentage of drug dissolved in a given time or the time taken for a certain percentage of drug to be dissolved, is correlated with certain parameter of the bioavailability. 1. COMPARISON OF PROFILES • The entire in vivo response time profile can be correlated to the entire dissolution rate time curve. • Some of the in vivo and in vitro parameters employed for correlation are as follows.
  35. 35. 35 In vitro data 1. Percent drug dissolution profile o o o o Percent drug dissolved at time t, Time taken for maximum amount of drug to dissolve. Total amt. of drug dissolved. Time for a certain percentage of drug to dissolve such as t30% t50% t90% In vivo data 1. Plasma conc. time profile o o o o o Plasma concentration at time t, Cmax, tmax, AUCot AUCo∞ t30%, t50%, t90% 2. Kinetic parameters o Dissolution rate constant o Dissolution half life 2. Pharmacokinetic parameters o Absorption & elimination rate constant & half life 3. Percent drug dissolved time profile o Percent drug dissolved at time t 3. Percent drug absorbed time profile 4. Statistical moment analysis o MDT 4. Statistical moment analysis o MRT, MAT
  36. 36. 36 3. DIRECT, DIFFERENTIAL- EQUATION- BASED in-vitro-in-vivo correlation (IVIVC) method = a novel method ▫ A new, differential equation-based in-vitro-in-vivo correlation (IVIVC) method is proposed that directly relates the time-profiles of in-vitro dissolution rates and in -vivo plasma concentrations by using one- or multi- compartment pharmacokinetic models and a corresponding system of differential equations. ▫ The rate of in-vivo input is connected to the rate of in-vitro dissolution through a general functional dependency that allows for time scaling and time shifting. A multiplying factor that accounts for the variability of absorption conditions as the drug moves along is also incorporated. ▫ Two data sets incorporating slow-, medium-, and fast-release formulations were used to test the applicability of the method, and predictive powers were assessed with a leave-oneformulation- out approach. All fitted parameters had realistic values, and good or acceptable fits and predictions were obtained as measured by plasma concentration mean squared errors and percent AUC errors. Introduction of step-down functions that account for the transit of the dosage form past the intestinal sites of absorption proved useful. ▫ By avoiding the integral transforms used in the existing deconvolution –
  37. 37. 37 WHATS IN STORE FOR THE FUTURE IVIVR (In vitro-in vivo relationship) • One possible substitution for IVIVC is IVIVR, with "R" denoting "relationship." • Hence, IVIVR need not be limited to straight-line relationships, which generally fails for IR products. • This IVIVR analysis has been applied to several formulations of metoprolol, piroxicam, and ranitidine. • This indicated that one intent of IVIVR should be to learn about the relative contribution of dissolution to a product's overall absorption kinetics.
  38. 38. 38 APPLICATIONS OF IVIVC A. IVIVC IN DRUG DELIVERY a. b. c. d. e. EARLY STAGES OF DRUG DELIVERY TECHNOLOGY DEVELOPMENT FORMULATION ASSESSMENT DISSOLUTION SPECIFICATIONS FUTURE BIOWAIVERS : For minor formulation and process changes IVIVC PARENTERAL DRUG DELIVERY : CAUSES OF FAILURE OF PARENTERAL IVIVC… I. Burst Release II. Potent Drugs & Chronic Therapy III. Limited volume of tissue fluids and Area of absorption at the site of administration, unlike following the oral route of administration. Therefore, it is very difficult to specify the in vitro dissolution conditions that reflect the observed differences in the in vivo plasma profiles corresponding to the in vitro release profiles.
  39. 39. 39 B. NEW IVIVC APPLICATIONS a. b. c. IVIVC FOR TRANSDERMAL ESTRADIOL SYSTEMS (Novel pharmaceuticals) WHY IVIVC FAIL FOR IMMEDIATE RELEASE DOSAGE FORM DISSOLUTION SIMULATORS I. Gronings model II. Sartorius dissolution simulator III. Sartorius membrane filter solubility simulator IV. Sartorius membrane filter absorption simulator DISSOLUTION SIMULATORS In order to enhance the capability of in vitro dissolution as a predictor of the in vivo behavior of dosage forms. But many of these attempts required highly complex and expensive apparatus with questionable advantage over traditional systems. 1. Gronings model:• It consists of two interconnecting flow through cells and a reservoir for the dissolution medium, all contained in a constant temperature water bath. • The dosage form disintegrates in the gastric part of the model and some of the drug particles are continuously pumped into the intestinal part.
  41. 41. 41 WHY IVIVC FAIL FOR IMMEDIATE RELEASE DOSAGE FORM • For Level A analysis, the fraction drug absorbed (Fa) is plotted against the fraction drug dissolved (Fd). The fraction drug absorbed profile is obtained by deconvoluting the plasma profile. Deconvolution is essentially a back calculation to answer the question: "What must the drug absorption profile have been, given the plasma profile?“ • A statistic from Level A analysis is r, the correlation coefficient. Its square r2, ranges from zero to one and is a measure of the strength of relationship between Fa against Fd. Often, results with sufficiently large r2 (e.g. greater than 0.9) yielded "a (successful) correlation." An r2 value that was too low resulted in a "no correlation" conclusion. • Only products with dissolution rate-limited absorption (and with complete absorption) can be expected to exhibit a Level A plot with a slope of one and zero intercept, immediate release products will "fail" the Level A method.
  42. 42. 42 IMPORTANT QUESTIONS 1. Explain IVIVC & IVIVR. Detail the methods for establishing IVIVC. 05 Note:- 3 times in board 2. Give the factors affecting IVIVC. 05 3. What factors are affecting the development of predictable IVIVC? 05 4. What is IVIVC? What are the criteria, objective and need for IVIVC? What are the levels for correlation? Why it fails for immediate release dosage forms? 06 5. What are the objectives of IVIVC? Describe different levels of correlation for IVIVC. 05
  43. 43. 43 REFERENCES • Guidance for Industry; Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. www.fda.gov/cder/guidance/index.htm • IVIVC: An Important Tool in the Development of Drug Delivery Systems; Gangadhar Sunkara, PhD, and Dakshina M. Chilukuri, PhD. http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=144 • Dissolution, Bioavailability and Bioequivalence by Hamed M. Abdou, Mack Publishing House. • IVIVC Vs IVIVR; James E. Polli, Ph.D. http://www.dissolutiontech.com/DTresour/800Articles/800_art1.html • In Vitro–In Vivo Correlation: Importance of Dissolution in IVIVC; J-M. Cardot, E. Beyssac, and M.Alric. Dissolution Technologies | FEBRUARY 2007 • IVIVC: Methods and Applications in Modified-Release Product Development; Harald Rettig and Jana Mysicka. Dissolution Technologies | FEBRUARY 2008. • Journal Metadata Search: Pharmaceutical Press - Journal of Pharmacy and Pharmacology 55(4); 495 (2003) • Pharmaceutical dissolution testing, Umesh V. Banakar • Dissolution, bioavailability & bioequivalence, Hamed M. Abdou.
  44. 44. 44 Ph. No. :- +918460378336 Address:- 44, Assiyana Society; Dugarvada Road, Taluko & City : Modasa State: Gujarat Country: India Email: sahil.pharm4@gmail.com BEST OF LUCK TO ALL . . . . . . . . . .
  45. 45. 45